Table 1 Second generation CD20 monoclonal antibodies
Monoclonal Ab | Ig type | Patients | Regimen | Overall response rate(%) | Adverse events | Reference |
|---|---|---|---|---|---|---|
Ofatumumab (OFA) | IgG1 Kappa | 116 | Ofatumumab (Refractory FL) 500 mg 1000mg | 13% 10% | Infections, rash, urticaria, pruritis, neutropenia, anemia, thrombocytopenia | [40] |
59 | O-CHOP (untreated FL) 500 mg 1000 mg | 90% 100% | Leucopenia, neutropenia | [41] | ||
61 | O-FC (Frontline therapy for CLL) 500 mg 1000 mg | 77% 73% | Neutropenia, thrombocytopenia, anemia, infection | [35] | ||
Veltuzumab | IgG1 | 82 | Veltuzumab (Relapsed/refractory B cell NHL) 80 to 750 mg/m2 | 44%(FL) 83%(MZL) 43%(DLBL) | Fatigue, pruritis, asthenia, fever, dyspnea, headache, infection | [42] |
Ocrelizumab | IgG1 | 47 | Ocelizumab (Relapsed/Refractory FL) 750mg/m2 | 38% | Infusion related reaction, nasopharyngitis, asthenia, lymphopenia, infection | [43] |